CY1117151T1 - METHOD FOR PREPARING LEVOTYROXIN SOLUTION - Google Patents
METHOD FOR PREPARING LEVOTYROXIN SOLUTIONInfo
- Publication number
- CY1117151T1 CY1117151T1 CY20161100064T CY161100064T CY1117151T1 CY 1117151 T1 CY1117151 T1 CY 1117151T1 CY 20161100064 T CY20161100064 T CY 20161100064T CY 161100064 T CY161100064 T CY 161100064T CY 1117151 T1 CY1117151 T1 CY 1117151T1
- Authority
- CY
- Cyprus
- Prior art keywords
- levothyroxine
- preparing
- levotyroxin
- solution
- thyroxine
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 abstract 6
- 229950008325 levothyroxine Drugs 0.000 abstract 5
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 abstract 5
- 239000007788 liquid Substances 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 abstract 1
- 208000024799 Thyroid disease Diseases 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229940034208 thyroxine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/055—Phenols the aromatic ring being substituted by halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Η λεβοθυροξίνη, επίσης γνωστή ως L-θυροξίνη, συνθετική Τ4, ή 3,5,3',5'-τετραϊωδο-L-θυρονίνη, αριθμός CAS 51-48-9, είναι μια συνθετική μορφή θυροξίνης, που χρησιμοποιείται ως υποκατάστατο ορμόνης για ασθενείς με παθήσεις του θυρεοειδούς. Η εφεύρεση αναφέρεται σε μια μέθοδο παρασκευής πόσιμης σύνθεσης λεβοθυροξίνης. Η μέθοδος σύμφωνα με την εφεύρεση οδηγεί σε υγρά σκευάσματα λεβοθυροξίνης τα οποία έχουν βελτιωμένη σταθερότητα κατά την αποθήκευση σε σύγκριση με γνωστά υγρά σκευάσματα λεβοθυροξίνης.Levothyroxine, also known as L-thyroxine, synthetic T4, or 3,5,3 ', 5'-tetraodio-L-thyronine, CAS number 51-48-9, is a synthetic form of thyroxine, used as a hormone substitute for patients with thyroid diseases. The invention relates to a method of preparing an oral composition of levothyroxine. The process according to the invention results in liquid levothyroxine preparations which have improved storage stability compared to known levothyroxine liquid preparations.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2011/051015 WO2012120338A1 (en) | 2011-03-10 | 2011-03-10 | Method for the preparaton of a levothyroxine solution |
| EP11711688.9A EP2683361B2 (en) | 2011-03-10 | 2011-03-10 | Method for the preparaton of a levothyroxine solution |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1117151T1 true CY1117151T1 (en) | 2017-04-05 |
Family
ID=44625617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161100064T CY1117151T1 (en) | 2011-03-10 | 2016-01-21 | METHOD FOR PREPARING LEVOTYROXIN SOLUTION |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9050307B2 (en) |
| EP (1) | EP2683361B2 (en) |
| CY (1) | CY1117151T1 (en) |
| DK (1) | DK2683361T3 (en) |
| ES (1) | ES2559818T5 (en) |
| HR (1) | HRP20151421T1 (en) |
| HU (1) | HUE028423T2 (en) |
| PL (1) | PL2683361T5 (en) |
| PT (1) | PT2683361E (en) |
| RS (1) | RS54524B1 (en) |
| SI (1) | SI2683361T1 (en) |
| WO (1) | WO2012120338A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9345772B1 (en) * | 2015-02-27 | 2016-05-24 | Nilesh Parikh | Liquid levothyroxine formulations |
| DE112016005058T5 (en) | 2015-11-04 | 2018-07-19 | Leiutis Pharmaceuticals Pvt Ltd | New levothyroxine formulations for oral use |
| NL2017110B1 (en) | 2016-07-05 | 2018-01-12 | Emp Levo Gmbh | Methods for the preparation of a levothyroxine solution |
| WO2018069805A2 (en) | 2016-10-10 | 2018-04-19 | Ftf Pharma Private Limited | Method for preparation of liquid oral composition of l-thyroxin |
| EP3311844A1 (en) * | 2016-10-18 | 2018-04-25 | Altergon S.A. | High-stability packaged solutions of t4 thyroid hormone |
| US9782376B1 (en) | 2016-12-01 | 2017-10-10 | Fresenius Kabi Usa Llc | Levothyroxine liquid formulations |
| US11241382B2 (en) | 2019-03-01 | 2022-02-08 | Altergon Sa | Administration regimen of compositions of T4 thyroid hormone with high oral absorption |
| GR1009815B (en) * | 2019-07-25 | 2020-09-15 | Ιουλια Κλεωνος Τσετη | Orally-administrated non-alcoholic preservative-free levothyroxine formulation treating hypothyroidism |
| EP4061331A1 (en) | 2019-11-22 | 2022-09-28 | Wockhardt Limited | Oral film composition comprising levothyroxine |
| WO2024227895A2 (en) * | 2023-05-02 | 2024-11-07 | Labomed Pharmaceutical Company S.A. | Oral solution comprising liothyronine sodium |
| GR1010807B (en) * | 2023-09-15 | 2024-10-24 | Ιουλια Κλεωνος Τσετη | Sealed singe-dose aqueous levothyroxine solution container suitable for oral administration |
| CN117919171B (en) * | 2024-03-22 | 2024-05-31 | 泊诺(天津)创新医药研究有限公司 | Preparation method of levothyroxine sodium oral liquid |
| WO2025253253A1 (en) | 2024-06-04 | 2025-12-11 | Ibsa Institut Biochimique Sa | Orodispersible solid composition in the form of film for oral administration of thyroid hormones |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3035974A (en) | 1960-02-18 | 1962-05-22 | Israel Murray | Compositions and method for the parenteral administration of thyroxine |
| CN1011118B (en) * | 1986-06-13 | 1991-01-09 | 天津医学院附属医院 | Method for preparing eye drops for treating cataract |
| GB9401891D0 (en) * | 1994-02-01 | 1994-03-30 | Boots Co Plc | Therapeutic agents |
| US20050059574A1 (en) | 2000-12-21 | 2005-03-17 | Irwin Klein | Compositions of stable T3 and methodes of use thereof |
| US20070045951A1 (en) † | 2003-02-21 | 2007-03-01 | Robertson Phillip J | Video game mask |
| JP5173832B2 (en) * | 2006-01-06 | 2013-04-03 | インターベツト・インターナシヨナル・ベー・ベー | Concentrated liquid thyroid hormone composition |
-
2011
- 2011-03-10 US US14/003,598 patent/US9050307B2/en active Active
- 2011-03-10 HU HUE11711688A patent/HUE028423T2/en unknown
- 2011-03-10 HR HRP20151421T patent/HRP20151421T1/en unknown
- 2011-03-10 RS RS20150872A patent/RS54524B1/en unknown
- 2011-03-10 EP EP11711688.9A patent/EP2683361B2/en active Active
- 2011-03-10 PT PT117116889T patent/PT2683361E/en unknown
- 2011-03-10 SI SI201130713T patent/SI2683361T1/en unknown
- 2011-03-10 PL PL11711688.9T patent/PL2683361T5/en unknown
- 2011-03-10 ES ES11711688T patent/ES2559818T5/en active Active
- 2011-03-10 WO PCT/IB2011/051015 patent/WO2012120338A1/en not_active Ceased
- 2011-03-10 DK DK11711688.9T patent/DK2683361T3/en active
-
2016
- 2016-01-21 CY CY20161100064T patent/CY1117151T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2683361B1 (en) | 2015-11-25 |
| RS54524B1 (en) | 2016-06-30 |
| EP2683361A1 (en) | 2014-01-15 |
| EP2683361B2 (en) | 2023-11-29 |
| PL2683361T3 (en) | 2016-04-29 |
| PT2683361E (en) | 2016-02-22 |
| WO2012120338A1 (en) | 2012-09-13 |
| US9050307B2 (en) | 2015-06-09 |
| US20140073695A1 (en) | 2014-03-13 |
| DK2683361T3 (en) | 2016-02-01 |
| ES2559818T3 (en) | 2016-02-16 |
| PL2683361T5 (en) | 2024-09-09 |
| HRP20151421T1 (en) | 2016-03-25 |
| ES2559818T5 (en) | 2024-06-27 |
| HUE028423T2 (en) | 2016-12-28 |
| SI2683361T1 (en) | 2016-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1117151T1 (en) | METHOD FOR PREPARING LEVOTYROXIN SOLUTION | |
| CY1125155T1 (en) | CRYSTAL FORMS OF PROLYL HYDROSYLASE INHIBITOR | |
| CY1122648T1 (en) | PROCESS FOR THE PREPARATION OF COMPOSITIONS CONTAINING HYALURONIC ACID AND MEPIVACAINE HYDROCHLORIDE | |
| CY1121150T1 (en) | NEUROACTIVE 19-ALCOXY-17-SUBSTITUTED STEROIDS, USEFUL IN TREATMENT METHODS | |
| CY1124208T1 (en) | SALTS OR CONCRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | |
| CY1119056T1 (en) | 2 ', 4', - DIFFluoro-2'-Methyl-Substituted Nucleoside Derivatization as HCV RNA Replication Inhibitors | |
| CY1120480T1 (en) | PYRAZOLOPYRIMIDINE COMPOUNDS | |
| CY1119731T1 (en) | PROCEDURE FOR THE PRODUCTION OF BITAL ACID PRODUCERS | |
| CY1116791T1 (en) | 4-Aryl-N-phenyl-1,3,5-triazine-amines containing a sulphoximinine group | |
| EA201390934A1 (en) | COMPOSITIONS AND METHODS OF FXR MODULATION | |
| CY1115043T1 (en) | pharmaceutical product | |
| CY1116835T1 (en) | NEW EUROPEAN EXECUTIVE TOY PRRSV | |
| EA201490569A1 (en) | POLYMORPHIC FORM OF PRIDOPIDINE HYDROCHLORIDE | |
| CY1123056T1 (en) | NEW FORM OF ADMINISTRATION OF RACECADOTRIL | |
| EA201592144A1 (en) | PHENOL DERIVATIVE, METHOD FOR ITS PREPARATION AND ITS APPLICATION IN MEDICINE | |
| CY1120378T1 (en) | Substituted Derivatized Butane Phosphonic Acid Binding Derivatives as Water Inhibitors | |
| MX2015014336A (en) | DERIVATIVES OF GLUTARIMIDE, USE OF THE SAME, PHARMACEUTICAL COMPOSITION BASED ON THE SAME AND METHODS TO PRODUCE DERIVATIVES OF GLUTARIMIDE. | |
| GEP20186868B (en) | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level | |
| CY1118514T1 (en) | METHOD FOR PREPARING PERMETREXIDIS AND SOLUTION SALT | |
| EA201391265A1 (en) | AMIDES OF INDOLKARBONIC AND BENZIMIDAZOLOSTERN ACIDS AS INSECTICIDES AND ACARICIDES | |
| EA201491818A1 (en) | METHOD OF OBTAINING OPTICALLY PURE AND OPTIONAL SUBSTITUTED DERIVATIVES OF 2- (1-HYDROXIALKYL) CHROMEN-4-SHE AND THEIR USE WHEN RECEIVING DRUGS | |
| CY1121484T1 (en) | SALT AND CRYSTAL FORMS OF AN SUSPENDER PLK-4 | |
| EA201490395A1 (en) | METHOD FOR OBTAINING PHARMACEUTICAL COMPOSITIONS CONTAINING FINGOLIMOD | |
| CY1116721T1 (en) | NEW UNIONS AS PROJECTS FOR HISTAMIN H3 RECEPTORS | |
| BR112017000584A2 (en) | aldosterone synthase inhibitors |